Tag: manufacturing

WAYNE, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Elemica, the leader in network-based digital supply chain management and provider of the premier multi-enterprise digital supply chain network for all companies buying, selling and servicing the process manufacturing industry, today announced that its Sales Order Management & Collaboration solution has achieved SAP® certification as integrated with RISE with SAP S/4HANA^® Cloud. This integration helps organizations to more efficiently use Elemica’s Sales Order Management & Collaboration solution before, during and after their SAP S/4HANA migration.   

SHENZHEN, CHINA, June 25, 2025 (GLOBE NEWSWIRE) -- The board of directors of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) announces the proposed secondary listing of the Company’s ordinary shares (“Shares”) on the Singapore Exchange Securities Trading Limited (the “SGX-ST”) by way of introduction (the “Proposed Secondary Listing”). The Proposed Secondary Listing, if proceeded, will not involve issuance of new shares, and the Shares will continue to be primarily listed and traded on the Hong Kong Stock Exchange thereafter.

HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- HyOrc Corporation (OTC: ASPZ), a clean energy technology company advancing advanced green methanol production systems, and hydrogen-based combustion systems for transport & off-grid power, is pleased to announce that Andrea Magalini has officially joined the Board of Directors as a Non-Executive Director.

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG